Freshfields is advising Alexion, AstraZeneca Rare Disease on its acquisition of LogicBio® Therapeutics, Inc. (NASDAQ: LOGC), a pioneering genomic medicine company. The proposed acquisition aims to rapidly accelerate Alexion’s growth in genomic medicines through LogicBio’s unique technology, experienced rare disease R&D team and expertise in pre-clinical development. More details about the transaction can be found here.

The Freshfields team is led by NY M&A Partner Sebastian Fain, Counsel Olaf Ehlers and Associates Anthony Paladino and Chinyere Obi. Partner Adam Golden, Principal Associate Philipp Lehmann and Associates Tanny Kang and Joshua Samuel are advising on Life Sciences transactional matters; Partner Lori Goodman and Associate Lina Zhu on executive compensation and employee benefits matters; Partners Justin Stewart-Teitelbaum and Mary Lehner and Counsel Laura Onken on US antitrust matters; Partner Simon Priddis and Senior Associate Jenny Leahy on EU antitrust matters; Partner Aimen Mir and Special Counsel Christine Laciak on foreign investment matters; Partner Robert Scarborough and Senior Associate David Mitchell on tax matters; and Partner Kyle Lakin and Associate Christian Scott Uhlig on finance matters.

ENDS